However, because Pfizer retained rights to use drug with specified types of combination therapies, it too could benefit from the MedImmune-CRI-Ludwig partnership.We are just beginning to scratch the surface of the immune system's potential as a new tool in cancer treatment,??? said Dr Jonathan Skipper, executive director of technology development at the Ludwig Institute, an international non-prof